XML 101 R69.htm IDEA: XBRL DOCUMENT v3.24.0.1
LICENSE, COLLABORATION AND OTHER REVENUE - Medice License Agreement Narrative (Details)
3 Months Ended 12 Months Ended
May 24, 2023
USD ($)
performanceObligation
Jun. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Disaggregation of Revenue [Line Items]        
Other long-term assets     $ 12,423,000 $ 5,372,000
Revenue recognized     3,738,000 29,574,000
Recognized revenue under agreement     194,623,000 292,484,000
Accounts receivable, net     39,290,000 40,284,000
Payables     14,635,000 $ 18,021,000
MEDICE Arzneimittel Pütter GmbH & Co. KG | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement        
Disaggregation of Revenue [Line Items]        
Percentage of net product margin on sales in collaborative arrangement 70.00%      
License | MEDICE Arzneimittel Pütter GmbH & Co. KG        
Disaggregation of Revenue [Line Items]        
Upfront payment $ 10,000,000      
Milestone eligible for $ 100,000,000      
Tiered royalties, expected timing of satisfaction period 12 years      
Termination of agreement by counterparty, written notice period 12 months      
Termination of agreement eligible by counterparty, period after effective agreement date 12 months      
Number of performance obligations | performanceObligation 1      
Proceeds from customers   $ 8,600,000    
Other long-term assets     1,400,000  
Revenue recognized     10,000,000  
License | MEDICE Arzneimittel Pütter GmbH & Co. KG | Minimum        
Disaggregation of Revenue [Line Items]        
Tiered royalties 10.00%      
License | MEDICE Arzneimittel Pütter GmbH & Co. KG | Maximum        
Disaggregation of Revenue [Line Items]        
Tiered royalties 30.00%      
License | MEDICE Arzneimittel Pütter GmbH & Co. KG, Side Letter        
Disaggregation of Revenue [Line Items]        
Upfront payment     0  
Recognized revenue under agreement     1,000,000  
Accounts receivable, net     900,000  
Contract assets     0  
Payables     $ 0